Protease inhibitors: Merck plans larger trials, expanded access.
James
J S
JS
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D018791:CD4 Lymphocyte Count; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D004345:Drug Industry; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006297:Health Services Accessibility; D006801:Humans; D016032:Randomized Controlled Trials as Topic
D017320:HIV Protease Inhibitors